TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)
Brief Summary: The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.


Options:
A: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
B: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine
C: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)
Brief Summary: The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
C: Arm Label: EPANOVA; Type: EXPERIMENTAL; Interventions: Drug: Epanova® (omega-3 carboxylic acids) | Arm Label: Corn oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: corn oil control | Intervention Type: DRUG; Name: Epanova® (omega-3 carboxylic acids); Assigned to Arm(s): EPANOVA | Intervention Type: DRUG; Name: corn oil control; Assigned to Arm(s): Corn oil
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving PTSD Treatments for Adults With Childhood Trauma
Brief Summary: The aim of this project is to investigate the effectiveness of phase-based trauma-focused therapy (PBT) and intensive trauma-focused therapy (I-TFT) for adult patients with PTSD related to childhood abuse.

We will carry out a RCT, randomizing 150 patients to receive either standard TFT, PBT or i-TFT. The effects will be assessed at two endpoints of treatment (4, 8 and 16 weeks) and after a 6 and 12 months follow-up in an intention-to-treat analysis.


Options:
A: Arm Label: Self Empowerment Groups; Type: EXPERIMENTAL; Interventions: Behavioral: Self Empowerment Groups, Behavioral: Financial Empowerment, Behavioral: Matched Savings | Arm Label: Financial Empowerment; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Empowerment, Behavioral: Matched Savings | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self Empowerment Groups; Assigned to Arm(s): Self Empowerment Groups | Intervention Type: BEHAVIORAL; Name: Financial Empowerment; Assigned to Arm(s): Financial Empowerment, Self Empowerment Groups | Intervention Type: BEHAVIORAL; Name: Matched Savings; Assigned to Arm(s): Financial Empowerment, Self Empowerment Groups
B: Arm Label: Immediate e-NET Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Arm Label: Wait List Control Group; Type: EXPERIMENTAL; Interventions: Behavioral: e-Net for Parents of Neurodiverse Children | Intervention Type: BEHAVIORAL; Name: e-Net for Parents of Neurodiverse Children; Assigned to Arm(s): Immediate e-NET Group, Wait List Control Group
C: Arm Label: Narrative Exposure Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): Narrative Exposure Therapy
D: Arm Label: Trauma-Focused Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Trauma-focused treatment | Arm Label: Emotion Regulation Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Trauma-focused treatment, Behavioral: Emotion regulation training | Arm Label: Intensive Trauma-Focused Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive Trauma-focused treatment | Intervention Type: BEHAVIORAL; Name: Trauma-focused treatment; Assigned to Arm(s): Emotion Regulation Treatment, Trauma-Focused Treatment | Intervention Type: BEHAVIORAL; Name: Emotion regulation training; Assigned to Arm(s): Emotion Regulation Treatment | Intervention Type: BEHAVIORAL; Name: Intensive Trauma-focused treatment; Assigned to Arm(s): Intensive Trauma-Focused Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Apneic Oxygenation Using High-flow Nasal Cannula in Morbidly Obese Patients Undergoing General Anesthesia
Brief Summary: Before going off to sleep patients are given oxygen to saturate blood with oxygen to extend time before a decrease in the level of oxygen in the blood occurs. During this period, obese patients have a faster decrease in the level of oxygen in their blood. This study uses a device called "high-flow nasal cannula" (HFNC), which delivers humidified high-flow oxygen through 2 small plastic tubes placed just inside nostrils. In the intensive care unit settings this device has been used extensively and has become a standard practice. Purpose of this study is to determine whether these high-flow nasal cannula increase the time safely when going to sleep during elective surgery.


Options:
A: Arm Label: High Flow nasal cannula oxygen (HFNC); Type: EXPERIMENTAL; Interventions: Device: OPTIFLOW/ AIRVO | Arm Label: STANDARD high flow Face Mask (HFFM); Type: ACTIVE_COMPARATOR; Interventions: Procedure: STANDARD Face Mask | Intervention Type: DEVICE; Name: OPTIFLOW/ AIRVO; Assigned to Arm(s): High Flow nasal cannula oxygen (HFNC) | Intervention Type: PROCEDURE; Name: STANDARD Face Mask; Assigned to Arm(s): STANDARD high flow Face Mask (HFFM)
B: Arm Label: Nasal high-flow oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Optiflow (Fisher & Paykel Healthcare) | Arm Label: Venturi mask oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Intervention Type: DEVICE; Name: Optiflow (Fisher & Paykel Healthcare); Assigned to Arm(s): Nasal high-flow oxygen therapy | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask oxygen therapy
C: Arm Label: Normoventilation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hyperventilation; Type: EXPERIMENTAL; Interventions: Procedure: Hyperventilation | Intervention Type: PROCEDURE; Name: Hyperventilation; Assigned to Arm(s): Hyperventilation
D: Arm Label: HFNC (High Flow Nasal Cannulae); Type: EXPERIMENTAL; Interventions: Device: HFNC | Arm Label: CON (control); Type: ACTIVE_COMPARATOR; Interventions: Device: CON (control) | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC (High Flow Nasal Cannulae) | Intervention Type: DEVICE; Name: CON (control); Assigned to Arm(s): CON (control)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Brief Summary: This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.


Options:
A: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
B: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Arm Label: Eptacog alfa and concizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab | Intervention Type: DRUG; Name: Eptacog alfa; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab
C: Arm Label: BAY94-9027 and Elocta; Type: EXPERIMENTAL; Interventions: Drug: Damoctocog (Jivi, BAY94-9027), Drug: Elocta | Arm Label: Elocta and BAY94-9027; Type: EXPERIMENTAL; Interventions: Drug: Damoctocog (Jivi, BAY94-9027), Drug: Elocta | Intervention Type: DRUG; Name: Damoctocog (Jivi, BAY94-9027); Assigned to Arm(s): BAY94-9027 and Elocta, Elocta and BAY94-9027 | Intervention Type: DRUG; Name: Elocta; Assigned to Arm(s): BAY94-9027 and Elocta, Elocta and BAY94-9027
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Brief Summary: This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.


Options:
A: Arm Label: Arm 1: rFVIII on demand first CS/EP then CS/ADJ; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) on demand | Arm Label: Arm 2: rFVIII on demand first CS/ADJ then CS/EP; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) on demand | Arm Label: Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) prophylaxis low-dose | Arm Label: Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) prophylaxis low-dose | Arm Label: Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) prophylaxis high-dose | Arm Label: Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP; Type: EXPERIMENTAL; Interventions: Biological: rFVIII (BAY81-8973) prophylaxis high-dose | Intervention Type: BIOLOGICAL; Name: rFVIII (BAY81-8973) on demand; Assigned to Arm(s): Arm 1: rFVIII on demand first CS/EP then CS/ADJ, Arm 2: rFVIII on demand first CS/ADJ then CS/EP | Intervention Type: BIOLOGICAL; Name: rFVIII (BAY81-8973) prophylaxis low-dose; Assigned to Arm(s): Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ, Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP | Intervention Type: BIOLOGICAL; Name: rFVIII (BAY81-8973) prophylaxis high-dose; Assigned to Arm(s): Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ, Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP
B: Arm Label: On-Demand; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Intervention Type: DRUG; Name: rFVIIIFc; Assigned to Arm(s): On-Demand, Prophylaxis
C: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
D: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: Turoctocog alfa | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab | Intervention Type: DRUG; Name: Turoctocog alfa; Assigned to Arm(s): Concizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Eye-Cervical Re-education Program (ECRP) to Decrease Pain and Increase Mobility in the Cervical Area Compared to a Combined Physiotherapy Protocol (CPP) in Patients With Chronic Neck Pain Symptoms.
Brief Summary: The aim of the present study is to value the effectiveness of an Eye-Cervical Re-education Program (ECRP) to decrease pain and increase mobility in the cervical area compared to a Combined Physiotherapy Protocol (CPP) in patients with chronic neck pain symptoms.


Options:
A: Arm Label: 1 Manual Therapy Utrecht; Type: EXPERIMENTAL; Interventions: Other: Manual Therapy Utrecht | Arm Label: 2 Physical Therapy - Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: OTHER; Name: Manual Therapy Utrecht; Assigned to Arm(s): 1 Manual Therapy Utrecht | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): 2 Physical Therapy - Exercise Therapy
B: Arm Label: Dry needling; Type: EXPERIMENTAL; Interventions: Other: Dry Needling | Arm Label: Ischemic compression; Type: EXPERIMENTAL; Interventions: Other: Ischemic Compression | Intervention Type: OTHER; Name: Dry Needling; Assigned to Arm(s): Dry needling | Intervention Type: OTHER; Name: Ischemic Compression; Assigned to Arm(s): Ischemic compression
C: Arm Label: positive CPR: research group; Type: EXPERIMENTAL; Interventions: Other: physical therapy treatment with aerobic exercise | Arm Label: negative CPR: research group; Type: EXPERIMENTAL; Interventions: Other: physical therapy treatment with aerobic exercise | Arm Label: positive CPR: control group; Type: ACTIVE_COMPARATOR; Interventions: Other: physical therapy treatment | Arm Label: negative CPR: control group; Type: ACTIVE_COMPARATOR; Interventions: Other: physical therapy treatment | Intervention Type: OTHER; Name: physical therapy treatment with aerobic exercise; Assigned to Arm(s): negative CPR: research group, positive CPR: research group | Intervention Type: OTHER; Name: physical therapy treatment; Assigned to Arm(s): negative CPR: control group, positive CPR: control group
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Combined Physiotherapy Protocol | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Other: EYE-CERVICAL RE-EDUCATION PROGRAM | Intervention Type: OTHER; Name: EYE-CERVICAL RE-EDUCATION PROGRAM; Assigned to Arm(s): Experimental Group | Intervention Type: OTHER; Name: Combined Physiotherapy Protocol; Assigned to Arm(s): Control Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Guided Meditation as an Adjunct to Enhance Postoperative Recovery: A Feasibility Study
Brief Summary: The primary purpose of this trial is to test the feasibility of implementing a meditation program in the perioperative period.


Options:
A: Arm Label: Standard group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Mind&Life (standard + intervention) group; Type: EXPERIMENTAL; Interventions: Behavioral: Mind&Life, Behavioral: Standard | Intervention Type: BEHAVIORAL; Name: Mind&Life; Assigned to Arm(s): Mind&Life (standard + intervention) group | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Mind&Life (standard + intervention) group, Standard group
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Mindfulness Based Stress Reduction (MBSR) program; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Healthy Living Course (HLC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness Based Stress Reduction (MBSR) program | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Healthy Living Course (HLC)
D: Arm Label: Diabetes Self Management Education (DSME) + Mind-STRIDE; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-STRIDE | Arm Label: DSME alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mind-STRIDE; Assigned to Arm(s): Diabetes Self Management Education (DSME) + Mind-STRIDE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prostaglandin Insert (Propess) Versus Trans-cervical Balloon Catheter for Out-patient Labour Induction: A Randomised Controlled Trial of Feasibility
Brief Summary: This study will randomise low-risk women to compare the effectiveness of trans-cervical balloon catheter for pre-induction cervical ripening for out-patient induction of labour with current practice (Propess). Women will be randomised to two treatment groups. The investigators wish to explore if such a trial is feasible, acceptable to women and what data collection is required for a future trial. Since no data exist, the investigators propose a study with approximately 60 women in each arm across two recruiting sites.


Options:
A: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Foley Catheter and Oxytocin; Type: EXPERIMENTAL; Interventions: Device: Foley Catheter, Drug: Oxytocin | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter and Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Foley Catheter and Oxytocin, Oxytocin
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: ARD (Atad Ripener Device) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: AID (Atad double balloon Instillation Device) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: folly catheter | Intervention Type: DEVICE; Name: ARD (Atad Ripener Device); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: AID (Atad double balloon Instillation Device); Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: folly catheter; Assigned to Arm(s): 3
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS Foley and oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: PROMS no Foley bulb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin, PROMS Foley and oxytocin
D: Arm Label: Cook Cervical balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Cook cervical balloon | Arm Label: Prostin E2 Vaginal suppository; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prostin E2 Vaginal Suppository | Intervention Type: DEVICE; Name: Cook cervical balloon; Assigned to Arm(s): Cook Cervical balloon | Intervention Type: DRUG; Name: Prostin E2 Vaginal Suppository; Assigned to Arm(s): Prostin E2 Vaginal suppository

Answer: D